Pharmaceutical Commerce - February 2023 Issue (PDF)

Mitigating Drug Shortages

Data displayed rapid and sustained B-cell depletion, with 97.2% of study patients with relapsing and primary progressive multiple sclerosis experiencing no relapses.

April 12th 2024

Pharma Pulse 4/18/24: Certain Biotech Investors Get an Early Look at Results, An Ethical Outlook for Obesity Drugs & more

Allen Jacques explains the history behind medications’ lack of supply, while offering ways to help alleviate their impact.

A Further Examination of Pharmacy Benefit Managers

The latest news for pharma industry insiders.

March 29th 2024

Novartis’ Fabhalta Shows Significant Promise in Reducing Proteinuria in Patients with IgA Nephropathy

Brandon Newman joins The Pharmaceutical Commerce Podcast to discuss the evolving role of PBMs, including the importance of drug price transparency.

LogiPharma Europe 2024: A Digital Capability Transformation

Data from the Phase III APPLAUSE-IgAN study showed a 38.3% reduction in proteinuria in patients treated with Fabhalta for IgA nephropathy compared to placebo.

Genentech Shares Promising Results from Phase III OCARINA II Study of Ocrevus for Elapsing, Primary Progressive Multiple Sclerosis

Panel discussion uncovers how to alter one’s digital know-how for use in temperature-controlled supply chain.

Related Content

Mitigating Drug Shortages

Data displayed rapid and sustained B-cell depletion, with 97.2% of study patients with relapsing and primary progressive multiple sclerosis experiencing no relapses.

April 12th 2024

Pharma Pulse 4/18/24: Certain Biotech Investors Get an Early Look at Results, An Ethical Outlook for Obesity Drugs & more

Allen Jacques explains the history behind medications’ lack of supply, while offering ways to help alleviate their impact.

A Further Examination of Pharmacy Benefit Managers

The latest news for pharma industry insiders.

March 29th 2024

Novartis’ Fabhalta Shows Significant Promise in Reducing Proteinuria in Patients with IgA Nephropathy

Brandon Newman joins The Pharmaceutical Commerce Podcast to discuss the evolving role of PBMs, including the importance of drug price transparency.

LogiPharma Europe 2024: A Digital Capability Transformation

Data from the Phase III APPLAUSE-IgAN study showed a 38.3% reduction in proteinuria in patients treated with Fabhalta for IgA nephropathy compared to placebo.